These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. Lane NE, Thompson JM, Strewler GJ, Kinney JH. J Bone Miner Res; 1995 Oct; 10(10):1470-7. PubMed ID: 8686502 [Abstract] [Full Text] [Related]
30. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Mosekilde L, Danielsen CC, Gasser J. Endocrinology; 1994 May; 134(5):2126-34. PubMed ID: 8156913 [Abstract] [Full Text] [Related]
32. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY. J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625 [Abstract] [Full Text] [Related]
33. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. Zhou H, Shen V, Dempster DW, Lindsay R. J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706 [Abstract] [Full Text] [Related]
34. Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. Iwamoto J, Takeda T, Sato Y, Shen CL, Yeh JK. Exp Anim; 2006 Oct; 55(5):457-66. PubMed ID: 17090962 [Abstract] [Full Text] [Related]
35. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. Rhee Y, Won YY, Baek MH, Lim SK. J Bone Miner Res; 2004 Jun; 19(6):931-7. PubMed ID: 15125792 [Abstract] [Full Text] [Related]
36. A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Søgaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE. Bone; 1997 May; 20(5):439-49. PubMed ID: 9145241 [Abstract] [Full Text] [Related]
37. Decreased bone anabolic effect of basic fibroblast growth factor at fatty marrow sites in ovariectomized rats. Pun S, Dearden RL, Ratkus AM, Liang H, Wronski TJ. Bone; 2001 Feb; 28(2):220-6. PubMed ID: 11182382 [Abstract] [Full Text] [Related]
38. Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Calcif Tissue Int; 2016 Nov; 99(5):489-499. PubMed ID: 27395059 [Abstract] [Full Text] [Related]
39. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2. Otomo H, Sakai A, Ikeda S, Tanaka S, Ito M, Phipps RJ, Nakamura T. J Bone Miner Metab; 2004 Nov; 22(5):404-14. PubMed ID: 15316861 [Abstract] [Full Text] [Related]
40. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]